Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review

被引:136
作者
McFarland, Lynne V. [1 ]
机构
[1] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA 98195 USA
来源
BMJ OPEN | 2014年 / 4卷 / 08期
关键词
ANTIBIOTIC-ASSOCIATED DIARRHEA; LACTOBACILLUS-PLANTARUM; 299V; IRRITABLE-BOWEL-SYNDROME; HUMAN INTESTINAL MICROFLORA; JAPANESE CEDAR POLLINOSIS; FECAL MICROBIOTA; BIFIDOBACTERIUM-LONGUM; SACCHAROMYCES-BOULARDII; BACTERIAL VAGINOSIS; HEALTHY-VOLUNTEERS;
D O I
10.1136/bmjopen-2014-005047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To assess the evidence for the claim probiotics can correct dysbiosis of the normal microbiota resulting from disease or disruptive events. Setting: Systematic review of published clinical trials of patients receiving a probiotic intervention for the prevention or treatment of various diseases. Data sources: Sources searched (1985-2013): PubMed, EMBASE, Cochrane Database of Systematic Reviews, CINAHL, AMED and ISI Web of Science. Three on-line clinical trial registries were searched: Cochrane Central Register of Controlled trials, MetaRegister of Controlled Trials and National Institutes of Health. Review methods: Included studies were randomised clinical trials of probiotic interventions having microbiological assays. Studies were evaluated following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for specific probiotic strains. A standard data extraction form was used to collect the raw data. Outcome measures: The primary outcome is the degree of microbiota correction by specific probiotic strains. Secondary outcome was the association between the degree of dysbiosis correction and clinical efficacy. Results: The review of the literature found three distinct study designs: model A (restoration) assayed patients enrolled with a healthy, undisturbed microbiota and then assayed postdisruptive event and probiotic therapy; model B (alteration) assayed patients with pre-existing disrupted microbiota and then postprobiotic therapy; model C (no dysbiosis) assayed volunteers with no disruptive event prebiotic and postprobiotic. From a total of 63 trials, 83% of the probiotic products using model A restored the microbiota, 56% using model B improved the microbiota and only 21% using model C had any effect on microbiota. Clinical efficacy was more commonly associated with strains capable of restoration of the normal microbiota. Conclusions: The ability to assess the degree of dysbiosis improvement is dependent on the enrolled population and the timing of microbiological assays. The functional claim for correcting dysbiosis is poorly supported for most probiotic strains and requires further research.
引用
收藏
页数:18
相关论文
共 112 条
  • [1] The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters
    Aagaard, Kjersti
    Petrosino, Joseph
    Keitel, Wendy
    Watson, Mark
    Katancik, James
    Garcia, Nathalia
    Patel, Shital
    Cutting, Mary
    Madden, Tessa
    Hamilton, Holli
    Harris, Emily
    Gevers, Dirk
    Simone, Gina
    McInnes, Pamela
    Versalovic, James
    [J]. FASEB JOURNAL, 2013, 27 (03) : 1012 - 1022
  • [2] Guidance on the scientific requirements for health claims related to gut and immune function EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
    Agostoni, Carlo
    Bresson, Jean-Louis
    Fairweather-Tait, Susan
    Flynn, Albert
    Golly, Ines
    Korhonen, Hannu
    Lagiou, Pagona
    Lovik, Martinus
    Marchelli, Rosangela
    Martin, Ambroise
    Moseley, Bevan
    Neuhaeuser-Berthold, Monika
    Przyrembel, Hildegard
    Salminen, Seppo
    Sanz, Yolanda
    Strain, Sean
    Strobel, Stephan
    Tetens, Inge
    Tome, Daniel
    van Loveren, Hendrik
    Verhagen, Hans
    [J]. EFSA JOURNAL, 2011, 9 (04)
  • [3] Composition and metabolism of the intestinal microbiota in consumers and non-consumers of yogurt
    Alvaro, Elise
    Andrieux, Claude
    Rochet, Violaine
    Rigottier-Gois, Lionel
    Lepercq, Pascale
    Sutren, Malene
    Galan, Pilar
    Duval, Yvonne
    Juste, Catherine
    Dore, Joel
    [J]. BRITISH JOURNAL OF NUTRITION, 2007, 97 (01) : 126 - 133
  • [4] [Anonymous], GEORGIAN MED NEWS
  • [5] [Anonymous], DIET SUPPL GUID DOC
  • [6] Barc MC, 2008, ANAEROBE, V14, P229, DOI 10.1016/j.anaerobe.2008.04.003
  • [7] IMPACT OF BIFIDOBACTERIUM-LONGUM ON HUMAN FECAL MICROFLORA
    BENNO, Y
    MITSUOKA, T
    [J]. MICROBIOLOGY AND IMMUNOLOGY, 1992, 36 (07) : 683 - 694
  • [8] Berggren Anna, 2003, Microbial Ecology in Health and Disease, V15, P160, DOI 10.1080/08910600410024825
  • [9] What is a health benefit? An evaluation of EFSA opinions on health benefits with reference to probiotics
    Binnendijk, K. H.
    Rijkers, G. T.
    [J]. BENEFICIAL MICROBES, 2013, 4 (03) : 223 - +
  • [10] EFFECT OF LACTIC-ACID PRODUCING BACTERIA ON THE HUMAN INTESTINAL MICROFLORA DURING AMPICILLIN TREATMENT
    BLACK, F
    EINARSSON, K
    LIDBECK, A
    ORRHAGE, K
    NORD, CE
    [J]. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1991, 23 (02) : 247 - 254